J Refract Surg. 2024 Jul;40(7):e480-e489. doi: 10.3928/1081597X-20240506-02. Epub 2024 Jul 1.
To evaluate the effectiveness, safety, and stability of a modified PRESBYOND Laser Blended Vision protocol (Carl Zeiss Meditec AG) for correcting hyperopic astigmatism and presbyopia, using Custom Refractive Software Master (CRSM) targeting over a 6-month period.
A total of 636 eyes of 318 patients with a mean age of 51.05 ± 4.71 years (range: 40 to 60 years) met the inclusion and exclusion criteria. All patients completed a 6-month follow-up. CRSM software was used to generate ablation profiles for the MEL90 excimer laser (Carl Zeiss Meditec AG). The target refraction was emmetropic for the dominant eyes and between -0.75 and -1.12 diopters (D) for the near eyes.
Visual and refractive results were studied separately by the dominant and non-dominant eyes. The mean attempt to correct for spherical equivalent refraction was +2.17 ± 1.16 D (range: -1.00 to +5.37 D). The mean attempted cylinder was -0.60 ± 0.75 D (range: -4.00 to 0.00 D). All eyes monocularly achieved uncorrected distance visual acuity (UDVA) of 20/25 or better after refractive treatment and 88% achieved 20/20. Binocularly all eyes achieved UDVA of 20/25 or better and 96.54% achieved 20/20. Ninety-eight percent of the patients maintained their corrected distance visual acuity before surgery and UDVA 6 months after surgery.
This hyperopic micro-anisometropia protocol with PRESBYOND Laser Blended Vision was an effective, safe, and well-tolerated refractive treatment. It was an effective procedure with excellent results for UDVA and uncorrected near visual acuity and demonstrates that binocular summation exists. .
评估使用 Custom Refractive Software Master (CRSM) 针对远视散光和老视的改良 PRESBYOND Laser Blended Vision 方案(卡尔蔡司公司)在 6 个月期间的有效性、安全性和稳定性。
共有 318 名患者的 636 只眼符合纳入和排除标准,平均年龄为 51.05 ± 4.71 岁(范围:40 至 60 岁)。所有患者均完成了 6 个月的随访。使用 CRSM 软件为 MEL90 准分子激光(卡尔蔡司公司)生成消融曲线。主导眼的目标屈光度为正视,近眼的目标屈光度为-0.75 至-1.12 屈光度(D)。
通过主导眼和非主导眼分别研究了视力和屈光结果。等效球镜的平均尝试矫正值为+2.17 ± 1.16 D(范围:-1.00 至+5.37 D)。平均尝试柱镜为-0.60 ± 0.75 D(范围:-4.00 至 0.00 D)。所有眼在屈光治疗后单眼均达到未矫正远视力(UDVA)20/25 或更好,88%达到 20/20。双眼均达到 UDVA 20/25 或更好,96.54%达到 20/20。98%的患者在术前和术后 6 个月均保持矫正远视力。
这种伴有 PRESBYOND Laser Blended Vision 的远视微散光方案是一种有效、安全且耐受性良好的屈光治疗方法。它是一种有效且结果出色的手术,可提高远视力和未矫正近视力,并证明存在双眼叠加。